Loading organizations...
Delaware Street Capital operates as an opportunistic hedge fund, specializing in investments within public equity markets. The firm employs a strategic approach to capital allocation, identifying and acting upon market inefficiencies to generate returns. Its operational framework is designed to navigate dynamic market conditions, focusing on targeted opportunities rather than broad market exposure.
The firm was founded by Andy, who serves as its managing principal. His insight into the complexities of the financial markets and a vision for an agile investment strategy led to the establishment of Delaware Street Capital. This foundation allowed for the creation of an investment vehicle capable of adapting to evolving economic landscapes.
Delaware Street Capital serves accredited investors seeking exposure to actively managed public equity strategies. The firm's long-term vision centers on consistent capital appreciation through a disciplined, research-driven investment process. It aims to deliver robust performance by leveraging its deep understanding of market trends and fundamental analysis.
Delaware Street Capital has 2 tracked investments across 1 company. The latest tracked deal is $20.6M Other Equity in Neos Therapeutics in February 2015.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 25, 2015 | Neos Therapeutics | $20.6M Other Equity | — | Burrill Life Sciences Capital Fund III, CAC, Crabtree Partners, Essex Capital Corporation, Presidio Partners |
| Mar 4, 2014 | Neos Therapeutics | $15.5M Series C | — | Burrill Life Sciences Capital Fund III, CAC, CMEA Capital, Crabtree Partners |